CRs and near CRs were observed across various subgroups, including IMDC risk groups, PD-L1 combined positive score, tumor stage, and lesion organ/sites in the lenvatinib plus pembrolizumab arm (Supplementary Table 6). The gene discussed is CD274; the disease is neoplasm.